BioSpace News Archive

CareDx, Inc., a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announces it will be participating in the Canaccord Genuity 40th Annual Growth Conference, scheduled to be held virtually August 11-13, 2020.

Lexicon Pharmaceuticals, Inc., reported financial results and provided a business update for the three months ended June 30, 2020.

Tonix Pharmaceuticals Holding Corp. announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will deliver a Company presentation during the SNN Network Virtual Investor Conference on Thursday, August 6, 2020, at 10:00 a.m. ET.

Phase 1 Single Ascending Dose Study is Intended to Support the Clinical Development of SYN-020 in Multiple Indications

Seegene, Inc. announced that U.S. Food and Drug Administration has further expanded the emergency use authorization for its Allplex™ 2019-nCoV Assay, a real-time RT-PCR test for SARS-CoV-2, the novel coronavirus responsible for the COVID-19 disease.

Synlogic, Inc., a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced the promotion of Antoine ‘Tony’ Awad to the position of Chief Operating Officer.

Second-quarter revenue of $2.7 billion decreased 4% on a reported basis, 1% on a constant currency basis and 2% on an operational basis1

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report second quarter 2020 financial results after the close of U.S. financial markets on Thursday, August 6, 2020. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corpo

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, announced today that its second quarter 2020 financial results will be released after the market closes on Thursday, August 6, 2020. Following the release, t

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for the company’s product candidate ganaxolone for the treatment of CDKL5 deficiency disorder (CDD) , a rare refractory form of pediatric epilepsy.